Many neurodegenerative diseases – including Alzheimer’s, vascular dementia, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, multiple sclerosis, progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) – occur as a result of the progressive death of neurons in different regions of the nervous system. Woolsey Pharmaceuticals focuses on neurodegenerative diseases.
Woolsey Pharmaceuticals does not discover new drugs. We are an indications discovery company. We discover new ways to use existing drugs for other diseases and conditions for which patients in need have no therapeutic solutions.
Developing a drug from scratch can take well over a decade and cost well in excess of $1 billion.
Repurposed drugs can have a much shorter route to regulatory approval, and they have a much higher overall rate of approval – and at a fraction of the cost of de novo drugs. For patients dying or suffering, speed to market can mean life or death.
Repurposed drugs also offer a lower risk approach to drug development, because of their known safety profile.
What’s more, by seeking out drugs for which there is a new biologic understanding and where existing human data support a new indication, Woolsey Pharmaceuticals can further lessen the risks inherent in drug discovery.
In late 2019, Woolsey licensed exclusive rights to the drug fasudil from a leading Japanese pharmaceutical company. Fasudil is approved in Japan and China in an IV formulation for the treatment of cerebral vasospasm.
Our drug, BRAVYL®, is an oral version of fasudil, and will be developed for other indications.
We currently have two clinical trials for BRAVYL, one for dementia patients who wander, and one for patients suffering from Progressive Supranuclear Palsy (PSP) or Corticobasal Syndrome (CBS).
Click the button below to learn more about our clinical trial in dementia patients who wander.
Click the button below to learn more about our clinical trial in patients suffering from PSP or CBS.